Latest News
Genentech's Lunsumio regimen improves progression-free survival in Phase III follicular lymphoma study
17 September 2026 - Biotechnology company Genentech, a member of the Roche Group (SIX: RO, ROG) (OTCQX: RHHBY), announced on Thursday that its Phase III CELESTIMO study of Lunsumio (mosunetuzumab-axgb) plus lenalidomide met its primary endpoint in re...
Bayer's Kerendia wins FDA approval for chronic kidney disease associated with type 1 diabetes
17 September 2026 - German pharmaceutical and life sciences company Bayer AG (ETR:BAYN) (OTC:BAYRY) said on Thursday that the US Food and Drug Administration (FDA) has approved Kerendia (finerenone) to reduce urinary albumin-to-creatinine ratio in ad...
ProBio and Kun Tuo collaborate to deliver integrated CDMO-CRO solutions for advanced therapies
17 September 2026 - ProBio Inc, a global contract development and manufacturing organisation (CDMO) involved in biologics and cell and gene therapies (CGT), announced on Wednesday a strategic collaboration with clinical research organisation (CRO) Ku...
Myosin Therapeutics chosen for 2026-2027 NCI Investor Initiatives Showcase
17 September 2026 - Myosin Therapeutics Inc, a clinical-stage biotechnology company developing a new class of therapies targeting cancer cell mechanics, announced on Thursday its selection as a 2026–2027 National Cancer Institute (NCI) Investor...
Sobi and Innate confirm strategic partnership
17 September 2026 - Biopharmaceutical company Swedish Orphan Biovitrum AB (Sobi) (STO:SOBI) and clinical-stage biotechnology company Innate Pharma SA (Euronext Paris:IPH) (Nasdaq:IPHA) confirmed on Wednesday that their previously announced strategic ...